Pharmacological Mechanism of Wumeiwan in Treating Lung Metastasis of Breast Cancer
10.13422/j.cnki.syfjx.20210516
- VernacularTitle:乌梅丸治疗乳腺癌肺转移的药理机制
- Author:
Yu-fei LIU
1
;
Tian AN
1
;
Hong YU
1
;
Dong-gui WAN
2
;
Ying-yi FAN
3
;
Xiao-hua PEI
4
Author Information
1. Beijing University of Chinese Medicine，Beijing 100029，China
2. China-Japan Friendship Hospital，Beijing 100029，China
3. Beijing University of Chinese Medicine Third Affiliated Hospital，Beijing 100029，China
4. Xiamen Hospital of Beijing University of Chinese Medicine，Fujian 361001，China
- Publication Type:Research Article
- Keywords:
Wumeiwan;
lung metastasis of breast cancer;
network pharmacology;
mechanism;
cinnamaldehyde
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(9):193-201
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the potential target and mechanism of Wumeiwan in the treatment of lung metastasis of breast cancer by network pharmacological analysis and experimental verification. Method:The databases of active ingredients and targets of Wumeiwan were established through Traditional Chinese Medicine Systems Pharmacology（TCMSP） Database and Analysis Platform，and the targets of lung metastasis of breast cancer were established through the GeneCards database and Online Mendelian Inheritance in Man（OMIM） database，and the data of Chinese medicine targets and disease targets were matched. Cytoscape 3.6.0 software was used to establish the network analysis of traditional Chinese medicine-active ingredients-therapeutic targets，and the interaction relationship between key target proteins was analyzed by STRING database. Target gene ontology（GO） analysis and Kyoto Encyclopedia of Genes and Genomes（KEGG） signal pathway enrichment analysis were performed by using the Biological Information Annotation Database. Result:A total of 108 possible important targets for Wumeiwan in the treatment of lung metastasis of breast cancer were found，including interleukin 6（IL6），cysteine aspartate-specific protease-3（CASP3），vascular endothelial growth factor A（VEGFA），epidermal growth factor receptor（EGFR），mitogen-activated protein kinase（MAPK8）， and others. GO enrichment analysis yielded 29 cell components（CC），1 218 biological processes（BP） and 125 molecular functions（MF） related to lung metastasis of breast cancer，and KEGG enrichment analysis yielded 118 pathways related to lung metastasis of breast cancer（P<0.05），including MAPK signaling pathway and apoptosis pathway. In vitro experiments showed that cinnamaldehyde， the active ingredient of Wumeiwan， could induce apoptosis，inhibit proliferation and migration of MCF7 cells，partially validating the predicted results of network pharmacology to a certain extent. Conclusion:The therapeutic effect of Wumeiwan on lung metastasis of breast cancer may be multi-target，multi-pathway and multi-mechanism. The results of this study provide more evidence for the clinical application of Wumeiwan.
